Clinical Trial Update: A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers [Phase 2]

View source ↗

Summary

Phase IIa trial of trametinib monotherapy for biliary tract cancers completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancers
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-03-03